CAJ | 학술논문

小细胞肺癌（small cell lung cancer, SCLC）具有复杂的异质性，由于细胞起源、发病机制和驱动基因尚不明确，SCLC的诊治进展缓慢，鲜有突破，迫切需要新的治疗策略提高SCLC疗效。肿瘤免疫治疗可提高免疫系统识别和排除肿瘤细胞的能力，且对正常组织影响轻微。目前已经开展了肿瘤疫苗、过继细胞免疫治疗、细胞因子、checkpoint抑制剂等治疗SCLC的临床研究，ipilimumab是最有前景的药物。免疫治疗有望为SCLC治疗带来新的希望，未来还需要对SCLC的异质性、免疫治疗靶点不明确、免疫治疗耐受等影响免疫治疗疗效的问题开展进一步研究。
소세포폐암（small cell lung cancer, SCLC）구유복잡적이질성，유우세포기원、발병궤제화구동기인상불명학，SCLC적진치진전완만，선유돌파，박절수요신적치료책략제고SCLC료효。종류면역치료가제고면역계통식별화배제종류세포적능력，차대정상조직영향경미。목전이경개전료종류역묘、과계세포면역치료、세포인자、checkpoint억제제등치료SCLC적림상연구，ipilimumab시최유전경적약물。면역치료유망위SCLC치료대래신적희망，미래환수요대SCLC적이질성、면역치료파점불명학、면역치료내수등영향면역치료료효적문제개전진일보연구。
Small cell lung cancer (SCLC) is complex heterogeneous due to unclear biological characteristics in terms of cell origin, pathogenesis and driver genes etc. Diagnosis and treatment of SCLC has been slowly improved and few breakthroughs have been discovered up to now. hTerefore new strategies are urgently needed to improve the effcacy of SCLC treatment. Tumor immunotherapy has potential to restore and trigger the immune system to recognize and eliminate tumor cells, notably it has only minimal adverse impact on normal tissue. Cancer vaccine, adoptive immunotherapy, cytokines and checkpoint inhibitors have now been launched for clinical treatment of SCLC. Ipilimumab is the most promising medicine of immunotherapy. Immunotherapy is expected to bring new vision to the treatment of SCLC. And further researches are needed on such problems affecting effcacy of immunotherapy as the heterogeneity of SCLC, the uncertainty of target for immuno-therapy, the immune tolerance, etc.